Fig. 7: Differences in temporal profiles of blood MX1 and IFI27 expression in naturally acquired respiratory virus infections, and delayed responses in the nose to virus challenge. | Nature Communications

Fig. 7: Differences in temporal profiles of blood MX1 and IFI27 expression in naturally acquired respiratory virus infections, and delayed responses in the nose to virus challenge.

From: SARS-CoV-2 human challenge reveals biomarkers that discriminate early and late phases of respiratory viral infections

Fig. 7

A Discrimination between SARS-CoV-2 infected (N = 20) and uninfected (N = 26) household contacts of index cases with COVID-19 by blood transcript levels of MX1 and IFI27, at participant recruitment (study day 0) and 7 days later. Data points represent individual study participants, summarised by box and whisker plots showing median ±interquartile range ± 1.5 xIQR. Discrimination accuracy is shown as AUROC point estimate and 95% confidence intervals. B Individual standardised blood transcript levels of MX1 against IFI27 for sequential samples before infection (baseline, N = 128) and at time points indicated (day0, N = 103; day 2, N = 106, day 4, N = 100; day 6, N = 102) after presentation within 48 hours of symptoms onset among prospectively recruited participants with unselected respiratory virus infections. C Loess smoothed summary (line ±95% CI) for standardised transcript levels of MX1 and IFI27 in blood (N = 17) and nose samples (N = 5-13 for different time points) from participants who developed replicative virus infection by time after SARS-CoV-2 challenge, and in blood (N = 16) and nose samples (N = 12-13 for different time points) from participants who developed replicative virus infection by time after H3N2 influenza challenge.

Back to article page